Analyst firms · Morgan Stanley · STVN
Morgan Stanley STVN price target and rating history
Stevanato Group S.p.A. (STVN) · Health Care
Morgan Stanley rates Stevanato Group S.p.A. (STVN) Equal-Weight with a $24 price target, as of its latest action on Dec 2, 2025. It has published 6 rating actions on STVN since August 2021, including 0 upgrades and 1 downgrade. Across 3 firms with a STVN price target in the last 12 months, the median target is $24. Morgan Stanley's target matches it.
- Current rating
- Equal-Weight
- Price target
- $24
- Median target, all firms
- $24
- Actions on STVN
- 6
Morgan Stanley price target on STVN
Every Morgan Stanley rating on STVN
- Dec 2, 2025
- Dec 3, 2024
- Aug 24, 2023
- Mar 9, 2022
- Aug 20, 2021
- Aug 10, 2021
How other firms rate STVN
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| William Blair | Mkt Perform | Nov 4, 2026 | |
| Deutsche Bank | Hold | Oct 7, 2026 | |
| UBS | Neutral | Sep 9, 2026 | |
| TD Cowen | Buy | $25 | Jun 16, 2026 |
| Wolfe Research | Outperform | $21 | Jun 2, 2026 |
| Morgan Stanley | Equal-Weight | $24 | Dec 2, 2025 |
Questions about Morgan Stanley and STVN
- What is Morgan Stanley's price target for STVN?
- Morgan Stanley's latest stated price target for Stevanato Group S.p.A. (STVN) is $24, from its action on Dec 2, 2025.
- What is Morgan Stanley's rating on STVN?
- Morgan Stanley rates STVN Equal-Weight, a neutral rating, as of Dec 2, 2025.
- When did Morgan Stanley last change its view on STVN?
- On Dec 2, 2025, Morgan Stanley resumes coverage at Equal-Weight, price target $24.
- How does Morgan Stanley's STVN target compare with other analysts?
- Across 3 firms with a STVN price target in the last 12 months, the median target is $24. Morgan Stanley's target matches it.
All Morgan Stanley ratingsSTVN news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.